Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 12/2015

01-11-2015 | Image of the Month

Molecular imaging of glutamate-carboxypeptidase II (prostate-specific membrane antigen) in malignant epithelioid hemangioendothelioma

Authors: Thorsten Derlin, Ulrich Baumann, Frank M. Bengel

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 12/2015

Login to get access

Excerpt

Prostate-specific membrane antigen (PSMA)-targeted positron emission tomography/computed tomography (PET/CT) holds great promise in refining the restaging of prostate cancer in the context of biochemical recurrence [1‐3]. Of note, some PSMA ligands are theranostic, i.e., the same ligand can be used for diagnostic imaging and subsequent radionuclide therapy [4]. …
Literature
1.
Cho SY, Gage KL, Mease RC, et al. Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med. 2012;53:1883–91.PubMedCentralCrossRefPubMed
2.
Eiber M, Maurer T, Souvatzoglou M, et al. Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy. J Nucl Med. 2015;56:668–74.CrossRefPubMed
3.
Afshar-Oromieh A, Haberkorn U, Schlemmer HP, et al. Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience. Eur J Nucl Med Mol Imaging. 2014;41:887–97.CrossRefPubMed
4.
Herrmann K, Bluemel C, Weineisen M, et al. Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy. J Nucl Med. 2015;56:855–61.CrossRefPubMed
5.
Chang SS, O'Keefe DS, Bacich DJ, Reuter VE, Heston WD, Gaudin PB. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res. 1999;5:2674–81.PubMed
Metadata
Title
Molecular imaging of glutamate-carboxypeptidase II (prostate-specific membrane antigen) in malignant epithelioid hemangioendothelioma
Authors
Thorsten Derlin
Ulrich Baumann
Frank M. Bengel
Publication date
01-11-2015
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 12/2015
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-015-3161-z

Other articles of this Issue 12/2015

European Journal of Nuclear Medicine and Molecular Imaging 12/2015 Go to the issue

Editorial

Prostate cancer recurrence: can PSA guide imaging?

Original Article

Biodistribution of the 18F-FPPRGD2 PET radiopharmaceutical in cancer patients: an atlas of SUV measurements

Original Article

Pseudarthrosis after lumbar spinal fusion: the role of 18F-fluoride PET/CT

Image of the Month

18Fluorocholine PET/CT in parathyroid carcinoma: a new tool for disease staging?

Original Article

The value of SPECT/CT in carpal boss

Guidelines

EANM procedural guidelines for radionuclide myocardial perfusion imaging with SPECT and SPECT/CT: 2015 revision